Drug Candidate is Distinctive RNA Therapy and Immunotherapy Developed at City of Hope for Treatment of Multiple Cancers
IND Filing a Key Milestone for Planned Phase 1 Clinical Trial to be Initiated at City of Hope
Scopus BioPharma Inc. (Nasdaq: "SCPS") today announced the submission of an investigational new drug application ("IND") to the United States Food and Drug Administration ("FDA") for its immuno-oncology RNA therapy for the treatment of multiple cancers. The IND filing is a key milestone for the planned Phase 1 clinical trial for B-cell non-Hodgkin lymphoma to be initiated at City of Hope.
https://finance.yahoo.com/news/scopus-biopharma-announces-ind-submission-132500201.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.